Published Online
on January 4, 2007

A more recent version of this article appeared on February 1, 2007

This Article Full Text (PDF) All Versions of this Article: 38/2/388    most recent 01.STR.0000254462.75851.22v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sena, E. Articles by Macleod, M. Search for Related Content PubMed PubMed Citation Articles by Sena, E. Articles by Macleod, M. Related Collections Animal models of human disease Related Article

Submitted on May 1, 2006
Revised on June 23, 2006
Accepted on July 17, 2006

Systematic Review and Meta-Analysis of the Efficacy of Tirilazad in Experimental Stroke

Emily Sena BSc; Philippa Wheble BSc; Peter Sandercock MD; and Malcolm Macleod PhD^*

From Clinical Neurosciences, University of Edinburgh, Scotland.

^* To whom correspondence should be addressed. E-mail: malcolm{at}apoptosis.freeserve.co.uk.

Background and Purpose--Tirilazad is a candidate neuroprotective drug with reported efficacy in animal models of stroke that was, however, without benefit in clinical trials. This apparent contradiction might be explained if the animal studies were falsely positive, if the clinical trials were falsely negative, or if tirilazad was not tested under the same conditions in animal and clinical studies. Here we use systematic review and meta-analysis to describe the characteristics and limits to the neuroprotective action of tirilazad in animal models of stroke.

Methods--Systematic review and meta-analysis of studies describing the efficacy of tirilazad in animal models of focal ischemia, in which outcome was measured as infarct volume and/or neurological score. Weighted mean difference random effects meta-analysis was used to measure overall efficacy in prespecified subgroups.

Results--Eighteen studies describing outcome in 544 animals were identified. Study quality (median score, 5/10; interquartile range, 4 to 6) was similar to that seen in systematic reviews of other candidate neuroprotective drugs. Tirilazad reduced infarct volume by 29.2% (95% confidence interval 21.1% to 37.2%) and improved neurobehavioral score by 48.1% (95% confidence interval 29.3% to 66.9%).

Conclusion--Tirilazad may have substantial efficacy in animal models of stroke, but this conclusion must be qualified because of the presence of potential sources of bias.

Related Article:

The Thr715Pro Polymorphism of the P-Selectin Gene Is Not Associated With Ischemic Stroke Risk

Julia Ferrari, Sandra Rieger, Georg Endler, Stefan Greisenegger, Marion Funk, Thomas Scholze, Wilfried Lang, Wolfgang Lalouschek, and Christine Mannhalter
Stroke 2007 38: 395-397. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				M. R. Macleod, H. B. van der Worp, E. S. Sena, D. W. Howells, U. Dirnagl, and G. A. Donnan Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality Stroke, October 1, 2008; 39(10): 2824 - 2829. [Abstract] [Full Text] [PDF]

				J. Minnerup, J. Heidrich, J. Wellmann, A. Rogalewski, A. Schneider, and W.-R. Schabitz Meta-Analysis of the Efficacy of Granulocyte-Colony Stimulating Factor in Animal Models of Focal Cerebral Ischemia Stroke, June 1, 2008; 39(6): 1855 - 1861. [Abstract] [Full Text] [PDF]

				N. A. Crossley, E. Sena, J. Goehler, J. Horn, B. van der Worp, P. M.W. Bath, M. Macleod, and U. Dirnagl Empirical Evidence of Bias in the Design of Experimental Stroke Studies: A Metaepidemiologic Approach Stroke, March 1, 2008; 39(3): 929 - 934. [Abstract] [Full Text] [PDF]

				C. L. Gibson, L. J. Gray, P. M. W. Bath, and S. P. Murphy Progesterone for the treatment of experimental brain injury; a systematic review Brain, February 1, 2008; 131(2): 318 - 328. [Abstract] [Full Text] [PDF]